

## Type 2 Diabetes in adults (medicines update) Committee meeting 4

**Date:** 18/09/2023

**Location:** Virtual

**Minutes:** Final

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>	
Waqaar Shah (Chair)	Present for notes 1 – 8
Chirag Bakhai	Present for notes 1 – 8
Neel Basudev	Present for notes 1 – 8 except part of item 6
Catherine Bewsey	Present for notes 1 – 8
Mimi Chen	Present for notes 1 – 8
Sithembile Thokozile Chinaire	Present for notes 1 – 8
Anne Dornhorst	Present until partway through item 6
Natasha Jacques	Present for notes 1 – 8
Sallianne Kavanagh	Present for notes 1 – 8 except part of item 6
Soon Song	Present for notes 1 – 8
John Turner	Present for notes 1 – 8

<b>In attendance:</b>		
Astrid Aregui	Senior Medical Editor	Present from item 7
Sarah Dwyer	Technical Analyst	Present for notes 1 – 8
Rupert Franklin	Senior Guideline Commissioning Manager	Present for notes 1 – 8 except part of items 6 and 7
Sarah Glover	Information Specialist	Present from partway through item 6
James Hawkins	Senior Health Economist	Present for notes 1 – 8
Lina Manounah	Technical Analyst	Present for notes 1 – 8
Caroline Mulvihill	Technical Adviser, Guideline	Present for notes 1 – 8

	Lead	
Tayyaba Mumtaz	Trainee Technical Analyst	Present for notes 1 – 8
Sade Naku	Health Economist	Present for notes 1 – 8
Adam O’Keefe	Project Manager	Present for notes 1 – 8
Nancy Pursey	Trainee Technical Analyst	Present for notes 1 – 8
Muksitur Rahman	Health Economist	Present for notes 1 – 8
Emily Terrazas-Cruz	Senior Research Fellow	Present for notes 1 – 8
Philip Williams	Finance Analyst	Present for notes 1 – 8
George Wood	Technical Analyst	Present for notes 1 – 8

<b>Observers:</b>	
Beatrice Downing, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8
Hugo Pedder, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8
Lesley Owen, Methods and Economics Team, Centre for Guidelines, NICE	Present for items 4 – 5 and from partway through item 7

<b>Apologies:</b>	
Dan Cuthbertson	Topic Adviser
Hugh Gallagher	Committee member
Sharon McCarthy	Committee member
Annette Swinkels	Committee member
Gosia Wamil	Committee member
Joseph Runicles	Information Specialist, NICE

<b>1. Welcome, introductions and apologies</b>
<p>The Chair welcomed the Committee members and attendees, including colleagues from the NICE Guidelines Technical Support Unit at University of Bristol to the fourth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair congratulated Committee member Sallianne Kavanagh on her recent appointment to Vice Chair for this guideline update committee.</p>
<b>2. Confirmation of matter under discussion, and declarations of interest</b>
The Chair confirmed that, for the purpose of managing conflicts of interest, the

matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, these are noted below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Sallianne Kavanagh	Committee member, Pharmacist	Acted as judge in a judging panel for the diabetes QIC awards (concessionary effort role - no reimbursement for time or opinion). QIC are affiliated with Sanofi, though the awards concern services and are not linked to pharmaceutical products.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Sithembile Thokozile Chinaire	Committee member, Diabetes Nurse Consultant	Speaker at PULSE PCN - Summer Symposium 20th July 2023 for DEXCOM – session title: The benefits and value of CGM (No product placement). Received an honorarium for presenting at the Symposium.	Direct, financial	Declare and participate. Not specific to the scope of the guideline update

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### 3. Minutes of previous meeting

The minutes of the previous meeting were accepted as a true and accurate record.

### 4. NMA approach

The Chair introduced Caroline Mulvihill, Guideline Lead (CM) who provided the committee with an update on the planned approach for the network meta-analyses planned in support of the guideline update.

### 5. Health economics plan

The Chair introduced Muksit Rahman, Health Economist (MR), who discussed the Health economic review strategy with the committee. MR also discussed some elements of the Health economic modelling with the committee and provided an update on how the NICE team plan to present health inequalities data for the committee's consideration later in guideline development.

### 6. Review Question 1.1 For different population subgroups, which individual and/or combinations of pharmacological therapies are most clinically and cost

**effective as initial treatment for the management of type 2 diabetes?**

**Metformin:**

- **Presentation of clinical evidence**
- **Presentation of health economic evidence**

The chair presented Lina Manounah, Tayyaba Mumtaz and Nancy Pursey, Technical Analysts, who presented further clinical evidence identified in support of Review Question 1.1. MR then presented the health economic evidence informing the review question.

**7. Review Question 1.1**

- **Committee discussion of the evidence**
- **Drafting of recommendations**
- **Inequalities considerations**

The Chair reminded the committee that due to a previously declared interest, Committee member Mimi Chen (MC) is partially excluded from drafting recommendations for people with CKD.

The committee discussed the evidence presented and their own clinical expertise and drafted updates to the current recommendations accordingly, noting that these will be revisited following the presentation of further evidence later in guideline development.

The committee also discussed how it might best address health inequalities considerations when developing the guideline update, with input from Lesley Owen, Technical Adviser (LO).

**8. AOB**

Adam O'Keefe, Project Manager (AO) outlined next steps before the Chair thanked participants and closed the meeting.

**Date of next meeting:** Guideline Committee Meeting 5: 16 October 2023

**Location of next meeting:** Virtual